ALMS

Sinker

Alumis Inc. · Healthcare · United States · $878M cap · $8.4M/day traded

$4.39 -9.2% · close 18 Nov · scored 19 Nov

Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.

3
Score
Get score and insider alerts
Quality
22
Value
28
Momentum
15

As of 19 Nov 2026, the MoatMap Score for Alumis Inc. (ALMS) is 3/100, ranked against 25,000+ stocks in 38 markets (Quality 22, Value 28, Momentum 15, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 27.0x
ROE
-110.9%
peers -29.9%
D/E
0.1x
peers 0.2x
Dividend %
—
trailing yield

ABOUT ALUMIS INC.

Read

Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral therapies for patients suffering from immune-mediated diseases. The company's competitive moat is built upon its proprietary drug discovery platform and a focused pipeline targeting specific immunological pathways with high unmet medical needs. It aims to differentiate through innovative treatments for chronic inflammatory conditions.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue———24.1M—7.2M7.2M25.8M3.5%
Net marginn/mn/mn/m-1011.7%—————
EPS-1.2-1.3-4.6-2.3—-3.5-3.3-2.9—
Share count123.4M123.4M123.4M104.7M-5.3%129.8M———
Balance sheet
Debt1.8M32.6M30.7M36.9M174.8%35.3M———
Equity-195.2M-339.3M260.1M301.3M15.8%————
Debt/equityn/mn/m0.1x0.1x—————
Cash flow
Op. cash flow-107.7M-130.0M-255.1M-369.5M—-320.1M———
Cash flow marginn/mn/mn/m-1536.5%—-4421.3%———
Investing CF-68.8M60.5M-113.8M287.9M—————
Financing CF101.6M89.7M492.4M2.1M—————

Cash on hand equals about 1.3 years of the operating cash used in the last twelve months. Spending on equipment or exploration and any new funding are not counted.

PRICE (1Y) · USD-36.9%
4.45.15.86.57.28 Oct29 Oct18 Nov
SMA 50SMA 200

Price checkNo clear trendExperimental

No clear trend: not near its 52-week low, and not in a steady uptrend.

SwingsVery bumpy

Swung more than 99% of stocks we rank over the past year (volatility 138% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend (this stock): None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$4.39
RSI (14)
23.3
52-Week Range-86.0% from high
Low $4.35High $31.35

SCORE BREAKDOWN

Quality
22
ROIC
-123.2%5.0
ROE
-110.9%8.3
GP/Assets
1.8%14.1
Op. Margin
-5938.1%2.6
FCF/Assets
-89.9%3.2
Piotroski
439.3
Int. Cover
—N/A
D/E Ratio
0.09x62.8
Current Ratio
5.57x76.0
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-0.8x25.0
P/FCF
—N/A
P/B
1.9x59.5
P/S
100.4x6.5
Div Yield
—N/A
Momentum
15
52W High %
14%3.6
RS 6M
-79%1.4
SMA 50/200
0.34x1.1
EPS Rev 4W
-2.5%14.9
EPS Rev 12W
+0.3%58.1
EPS Improve
+17%34.5
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$878M
P/E (Forward)
-1.9x
Gross Margin
100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALMS are excluded.

TickerCompanyMkt CapScore
ALMSAlumis Inc.(you)$878M3
KURAKura Oncology, Inc.$855M5
CTYCity Therapeutics, Inc.$1.0B3
OBXObsidian Therapeutics, Inc.$864M6
ANNXAnnexon, Inc.$711M3
CRVSCorvus Pharmaceuticals, Inc.$886M7
AKTSAktis Oncology, Inc.$875M8
950260.KQIngenia Therapeutics Inc.$808M6
SVRASavara Inc.$867M9
IAMIambic Therapeutics, Inc.$676M5

Peer medians: ROE -29.9% · P/E 27.0x · Gross margin 63.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Alumis Inc. (ALMS): Stock Score Summary

Alumis Inc. (ALMS) has a MoatMap Score of 3/100 based on Quality (22/100), Value (28/100), and Momentum (15/100) factor scores.

Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral therapies for patients suffering from immune-mediated diseases. The company's competitive moat is built upon its proprietary drug discovery platform and a focused pipeline targeting specific immunological pathways with high unmet medical needs. It aims to differentiate through innovative treatments for chronic inflammatory conditions.

Director dealings

From 2 Jan 2026 to 19 Nov 2026, MoatMap's records hold 14 sales and 4 purchases of Alumis Inc. (ALMS) shares by its directors. The largest: AKKARAJU SRINIVAS bought 588,235 shares at $17.00 on 9 Jan 2026 (about $10.0M).

  • 2 Nov 2026: Bradley Mark Christopher sold 623 shares at $6.52 (about $4K)
  • 2 Nov 2026: Drappa Jorn sold 593 shares at $6.52 (about $4K)
  • 2 Nov 2026: Goldstein David M sold 629 shares at $6.52 (about $4K)
  • 2 Nov 2026: Hardiman Roy C. sold 652 shares at $6.52 (about $4K)
  • 2 Nov 2026: Pangali Sanam sold 332 shares at $6.52 (about $2K)
ALMS insider filings, last 180 days

Key Financial Metrics

Price$4.39
Market Cap$878M
P/E (Forward)-1.90
Price/Book1.92
Return on Equity-110.9%
Return on Invested Capital-123.2%
Debt/Equity0.09x
Gross Margin100.0%
Operating Margin-5938.1%
Revenue Growth-7.7%
Free Cash Flow$-370M

Alumis Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Alumis Inc.’s (ALMS) MoatMap Score?
The MoatMap Score for Alumis Inc. (ALMS) is 3/100. It is a composite of Quality (22), Value (28), and Momentum (15), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Alumis Inc. have an economic moat?
Alumis Inc. (ALMS) has a Quality factor score of 22/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Alumis Inc. in?
Alumis Inc. (ALMS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).